Nutrition Strategies for Peptide Users vs. Steroids and SARMs

Your Diet Matters More on Peptides Than on Gear

High-dose anabolic steroids are a sledgehammer. They crank up protein synthesis and nitrogen retention so strongly that they build muscle even without training. In a 1996 trial, men given 600 mg of testosterone enanthate a week for 10 weeks gained muscle size even if they didn't lift (Bhasin et al.).

Peptides aren't like that. A GHRH/GHRP stack like CJC-1295 and Ipamorelin tells the pituitary to release more growth hormone, but GH is just the signal. The body still needs the raw materials, from amino acids to vitamins and minerals, to actually build tissue in response to that signal. Think of it this way: peptides send the work order to the construction site, but diet is the truck that delivers the bricks and mortar.

The signal itself is also weaker than forum guides suggest. In the longest trial of a growth hormone secretagogue, 65 healthy adults aged 60-81 took oral MK-677 (25 mg daily) or placebo. After a year, fat-free mass rose about 1.1 kg on MK-677 and fell slightly on placebo. Strength didn't change (Nass et al., 2008). No trial has measured muscle gain with CJC-1295 or ipamorelin; our comparison of peptide and steroid mechanisms and results covers that gap. So diet carries more of the load for peptide users.

Caloric Environment: Match Your Fuel to Your Goal

Total energy intake is the foundation. The right caloric environment depends on why someone is using peptides.

For Growth (GHRPs, GHRHs, MK-677)

Most users running a growth-focused stack eat in a caloric surplus. Building new muscle tissue in a deficit is much harder, no matter how much GH is pulsing. The new tissue has to be built from something.

Community guides usually describe a modest surplus of 300-500 calories above maintenance, not a dirty bulk. They often add that higher GH/IGF-1 levels improve nutrient partitioning, steering those extra calories toward muscle rather than fat. That's plausible but largely untested for these peptides. In the MK-677 trial, total fat didn't change and limb fat rose more than on placebo. Appetite went up for the first few months. Fasting glucose also rose by about 5 mg/dL and insulin sensitivity fell, which is why glucose control comes up among the long-term risks of GH secretagogues. A 2,000-calorie surplus will still add fat with or without peptides.

For Healing & Recovery (BPC-157, TB-500)

Here, the goal is repair, not hypertrophy. A surplus isn't necessarily needed, but a steep deficit works against it. Tissue repair is an energy-intensive process: the body needs fuel to rebuild damaged collagen fibers and manage inflammation. Cutting calories hard to chase abs while trying to heal a nagging tendon with BPC-157 sends conflicting signals.

Community advice is usually maintenance calories, or a very slight deficit (about 200 calories) at most, until the injury heals. The healing claims for both peptides rest almost entirely on animal studies: as of October 2026, no controlled human trial of BPC-157 or the TB-500 fragment has published results.

For Fat Loss (Fragment 176-191, AOD9604)

This is the one time a deficit is the whole point. Peptides in this category were designed to enhance lipolysis (the release of fatty acids from fat cells), based mainly on rodent studies. But they don't vaporize fat. An energy deficit is still needed so the body actually burns those mobilized fatty acids for fuel.

In people, the fat-loss case hasn't held up. AOD-9604, a modified version of the hGH 176-191 fragment, was tested by its developer in oral and IV trials. In the largest, the OPTIONS Phase 2b trial, 536 adults with obesity took oral AOD-9604 (0.25 to 1 mg daily) or placebo alongside a supervised diet and exercise program for 24 weeks. Weight loss at 12 weeks (the primary endpoint) wasn't significantly different from placebo. The developer ended obesity development in February 2007.

In a December 2024 review for its Pharmacy Compounding Advisory Committee, FDA concluded that in most of the studies it identified, AOD-9604 "failed to show benefit for weight reduction when compared to placebo." FDA found no human data for subcutaneous injection, the route users describe. We found no human trial of unmodified Fragment 176-191.

So the key is a controlled deficit combined with high protein intake to preserve muscle. The OPTIONS trial effectively tested diet and exercise with and without AOD-9604, and adding the peptide made no significant difference. Most users who post about AOD-9604 also describe no noticeable change; a minority report losing inches.

Protein: The Non-Negotiable Raw Material

If calories are the foundation, protein is the frame of the house. Forum guides often say that peptides which signal for growth and repair increase the body's demand for amino acids. No study has measured protein needs in peptide users, so research on lifters in general is the best guide.

Many of those guides push intake to 1.2-1.5 grams per pound of bodyweight (about 2.6-3.3 g/kg) during a cycle, so that amino acids are on hand when a GH pulse arrives. The research points lower. The International Society of Sports Nutrition (ISSN) 2017 position stand calls 1.4-2.0 g/kg a day (about 0.6-0.9 g per pound) sufficient for most exercising people. It adds that 2.3-3.1 g/kg (about 1.0-1.4 g per pound) may be needed to keep lean mass in resistance-trained people during a calorie deficit. A 2018 meta-analysis of 49 trials found no further gain in fat-free mass above about 1.6 g/kg a day (Morton et al.).

Quality and timing matter, too. Leucine-rich sources like whey and red meat are favored because leucine is the primary trigger for muscle protein synthesis. ISSN suggests 20-40 g of protein per serving, spread evenly every 3-4 hours, which fits the 4-6 meals a day many lifters already eat.

Users commonly inject GH secretagogues on an empty stomach because food is thought to blunt the GH pulse. In a 2002 study of six young adults, a 100 g glucose drink or an IV fat infusion cut the GH response to IV ghrelin by roughly 40-60% (Broglio et al.). No study has tested whether meal timing changes results with subcutaneous ipamorelin or CJC-1295.

Micronutrients: The Spark Plugs for Peptide Pathways

Several micronutrients are cofactors for the pathways these peptides target, but the evidence concerns deficiency. We found no study showing that extra amounts improve the response to any peptide in people who already get enough.

For supplements used without peptides, see peptides versus natural supplements.

What We Still Don't Know

Peptides are often described as potent signaling molecules that amplify the results of what someone is already doing. For most of them, that hasn't been tested in people. No trial has measured whether protein intake or calorie level changes the response to the GH-releasing or healing peptides.

Steroids and SARMs have clearer human data on lean mass. In a 21-day trial of 76 healthy men, the SARM LGD-4033 (0.1-1.0 mg daily) raised lean body mass in a dose-dependent way, while lowering HDL cholesterol (Basaria et al., 2013). Two questions remain open for peptide users: whether the glucose rise seen with MK-677 calls for changes in carbohydrate intake, and whether protein needs really rise during a GH secretagogue cycle.

Comparison table

For how testing and sanctions work for each class, see peptides and anti-doping rules.